San Francisco, California 94115


The hypothesis being tested is that in patients with stable claudication and documented PAD, omega-3 supplementation for 1 month will lead to improvement in endothelial function as measured by flow-mediated, brachial artery vasodilation (FMD), as well as improvement in the vascular inflammatory profile as measured by a panel of established circulating inflammatory biomarkers.


Inclusion Criteria: - intermittent claudication - resting or exercise Ankle-Brachial Index (ABI) <0.9 - age 50 and more Exclusion Criteria: - critical limb ischemia - hypersensitivity/allergies to fish or seafood - already on omega-3 fatty acids or equivalent - significant renal, hepatic, and inflammatory disease - concurrent severe infections - acute illness (MI, stroke, major surgery within 30 days) - receiving immunosuppressive medications or steroids



Primary Contact:

Principal Investigator
Marlene Grenon, MD
University of California, San Francisco

Sukaynah Khetani, BS
Phone: 415-353-4368

Backup Contact:

David Cheng, MD
Phone: 415-221-4810 ext. 4708

Location Contact:

San Francisco, California 94115
United States

Sukaynah Khetani
Phone: 415-221-4810

Site Status: Recruiting

Data Source:

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.